NCT06590961 - UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Relapsed/Refractory B-cell Malignancies

Interventions

DRUG

UBX-303061

UBX-303061 oral dosage

Trial Locations (11)

44718

RECRUITING

Gabrail Cancer Center, Canton

48109

RECRUITING

University of Michigan, Ann Arbor

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

87-100

NOT_YET_RECRUITING

MICS Centrum Medyczne Toruń, Torun

02-172

NOT_YET_RECRUITING

Pratia, MTZ Clinical Research, Warsaw

40-519

NOT_YET_RECRUITING

Pratia, Oncology Katowice, Katowice

62-065

NOT_YET_RECRUITING

AidPort, Grodzisk Wielkopolski

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

07345

RECRUITING

The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul

All Listed Sponsors

lead

Ubix Therapeutics, Inc.

INDUSTRY